Breakthrough

Articles 1

EGFR mutation, as one of the most common driving genes in NSCLC, has an incidence rate of approximately 50% in lung adenocarcinoma patients in China [1]. In recent years, EGFR-TKI has brought good survival prognosis to EGFR mutation positive patients, but there are still some patients who are not sensitive to EGFR-TKI treatment in clinical practice.

2023-06-04